FIGURE 4 Novel drug modalities for NRF2 activation Up to date, the only NRF2 activators in clinical use are DMF for MS (Rosito et al., 2020), and more recently Omaveloxolone, a semisynthetic terpenoid with potent NRF2-activating effects gained FDA approval in Februrary 2023 for the treatment of Friederichs ataxia ( However, most NRF2 activators are of electrophilic nature and exhibit unpredictable poly-pharmacology
Stancheva R, Paunova-Krasteva T, Topouzova-Hristova T, Stoitsova S, Petrov P, Haladjova E
Some peoples bodies just dont absorb it well that way
Historically, surgery has been the most established and preferred method for cancer treatment, while radiation therapy was first employed to treat localized cancers in the 1960s (Khan et al., 2019)